2GNG image
Entry Detail
PDB ID:
2GNG
Title:
Protein kinase A fivefold mutant model of Rho-kinase
Biological Source:
Source Organism:
PDB Version:
Deposition Date:
2006-04-10
Release Date:
2006-05-23
Method Details:
Experimental Method:
Resolution:
1.87 Å
R-Value Free:
0.25
R-Value Work:
0.19
R-Value Observed:
0.19
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:cAMP-dependent protein kinase, alpha-catalytic subunit
Mutations:L49I, V123M, E127D, Q181K, T183A
Chain IDs:A
Chain Length:350
Number of Molecules:1
Biological Source:Bos taurus
Polymer Type:polypeptide(L)
Description:cAMP-dependent protein kinase inhibitor alpha
Chain IDs:B (auth: I)
Chain Length:20
Number of Molecules:1
Biological Source:
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
SEP A SER PHOSPHOSERINE
TPO A THR PHOSPHOTHREONINE
Primary Citation
Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity
J.Biol.Chem. 281 24818 24830 (2006)
PMID: 16699172 DOI: 10.1074/jbc.M512374200

Abstact

Controlling aberrant kinase-mediated cellular signaling is a major strategy in cancer therapy; successful protein kinase inhibitors such as Tarceva and Gleevec verify this approach. Specificity of inhibitors for the targeted kinase(s), however, is a crucial factor for therapeutic success. Based on homology modeling, we previously identified four amino acids in the active site of Rho-kinase that likely determine inhibitor specificities observed for Rho-kinase relative to protein kinase A (PKA) (in PKA numbering: T183A, L49I, V123M, and E127D), and a fifth (Q181K) that played a surprising role in PKA-PKB hybrid proteins. We have systematically mutated these residues in PKA to their counterparts in Rho-kinase, individually and in combination. Using four Rho-kinase-specific, one PKA-specific, and one pan-kinase-specific inhibitor, we measured the inhibitor-binding properties of the mutated proteins and identify the roles of individual residues as specificity determinants. Two combined mutant proteins, containing the combination of mutations T183A and L49I, closely mimic Rho-kinase. Kinetic results corroborate the hypothesis that side-chain identities form the major determinants of selectivity. An unexpected result of the analysis is the consistent contribution of the individual mutations by simple factors. Crystal structures of the surrogate kinase inhibitor complexes provide a detailed basis for an understanding of these selectivity determinant residues. The ability to obtain kinetic and structural data from these PKA mutants, combined with their Rho-kinase-like selectivity profiles, make them valuable for use as surrogate kinases for structure-based inhibitor design.

Legend

Protein

Chemical

Disease

Primary Citation of related structures